JAMP ENALAPRIL 2.5 MG
ENALAPRIL MALEATE : 2.5 MG · DIN 02474786 · JAMP PHARMA CORPORATION
Health Canada status: MARKETED
What is JAMP ENALAPRIL?
JAMP ENALAPRIL 2.5 MG contains ENALAPRIL MALEATE : 2.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02474786, held by JAMP PHARMA CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 25-Feb-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JAMP ENALAPRIL used for?
Essential or renovascular hypertension; symptomatic congestive heart failure; asymptomatic left ventricular dysfunction (EF ≤35%).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02474786 |
|---|---|
| Brand name | JAMP ENALAPRIL |
| Generic / active ingredient | ENALAPRIL MALEATE : 2.5 MG |
| Manufacturer | JAMP PHARMA CORPORATION |
| Strength | 2.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09AA02 ENALAPRIL |
| AHFS class | 24:32.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 25-Feb-2019 |
| Original market date | 2019-02-25 00:00:00 |
How is it administered?
Hypertension: 10-40 mg/day. CHF: 5-20 mg/day. Start low (2.5-5 mg). Max 40 mg/day. Adjust for renal impairment. Splitting tablets not advised.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (refer to section 11). Typical range 15-30°C.
How is it supplied?
Bottles of 100 tablets (2.5 mg); Bottles of 100 and 500 tablets (5 mg, 10 mg, 20 mg).
Contraindications
Hypersensitivity; history of ACEI-related angioedema; hereditary/idiopathic angioedema; combo with aliskiren in diabetes/renal impairment; combo with neprilysin inhibitors (e.g. sacubitril).
Warnings and precautions
Risk of angioedema (can be fatal); symptomatic hypotension; neutropenia/agranulocytosis; dual blockade of RAS; cough; hypoglycemia in diabetics.
What can be used instead?
Other Canadian products sharing ATC code C09AA02 ENALAPRIL. 36 of 100 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT ENALAPRIL | 16 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02291908 |
| ACT ENALAPRIL | 2 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02291878 |
| ACT ENALAPRIL | 4 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02291886 |
| ACT ENALAPRIL | 8 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02291894 |
| APO-ENALAPRIL | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02019892 |
| APO-ENALAPRIL | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02020025 |
| APO-ENALAPRIL | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02019906 |
| APO-ENALAPRIL | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02019884 |
| ENALAPRIL | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02400677 |
| ENALAPRIL | 16 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02442981 |
Who else supplies ENALAPRIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ENALAPRIL appears in 2538 registered pack listings across 12 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.